On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab. These podcasts will review the evidence behind the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults study (OUtMATCH) that led to this indication and discuss important considerations in implementing omalizumab for food allergy in your practice. (Non-CME)

Part 1: Reviewing the Evidence
Robert Wood, MD; Brian Vickery, MD; Gerald Lee, MD

Download MP3

Part 2: Implementation Into Practice
Sharon Chinthrajah, MD; Brian Vickery, MD; Gerald Lee, MD

Download MP3

Additional Resources for This Episode